To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification: transactions by persons discharging managerial responsibilities & persons closely associated with them

Release Date: 21/06/2022 17:00
Code(s): MEI     PDF:  
Wrap Text
Notification: transactions by persons discharging managerial responsibilities & persons closely associated with them

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(’Mediclinic’, the ‘Company’, or the ’Group’)


21 June 2022

NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM

Vesting of awards under the Company's Long-term Incentive (‘LTI’) Plan

This notification sets out details of the vesting of awards over ordinary shares in Mediclinic (’Shares’)
granted to persons discharging managerial responsibilities (’PDMRs’) on 19 June 2019 under the
Company’s LTI Plan (the ‘LTI Plan Awards’), in accordance with the remuneration policy approved by
shareholders in July 2017. These awards were structured as conditional awards vesting on the third
anniversary of the date of grant, subject to the satisfaction of performance conditions over the three-
year period. The LTI Plan Awards of executive directors of Mediclinic are subject to a further two-year
holding period following the third anniversary of the date of grant, with no further performance conditions
attached during the holding period.

On 19 May 2022, the Remuneration Committee approved the vesting of the LTI Plan Awards granted
to the PDMRs listed in the table below at 12.1% of maximum based on the achievement against
performance targets. These awards vested on 20 June 2022 and will be settled in cash based on the
middle-market quotation of a share on 17 June 2022, being 457.40 pence per share. The amount settled
includes the value of dividends attributable to the vested shares during the period between the date of
grant and the date of vesting, being a total of 3.20 pence per share.

 Name                                  Director/           Number of              Cash settlement
                                       PDMR               Shares vested             (including
                                                                                     dividend
                                                                                   equivalents)
 David John Hadley                     PDMR                    16 621                  £76 556
 Gert Cornelis Hattingh                PDMR                     9 857                  £45 401
 Dr Dirk Cornelius le Roux             PDMR                     7 739                  £35 646
 Dr Daniel Liedtke                     PDMR                    15 610                  £71 900
 Magnus Oetiker                        PDMR                    13 157                  £60 601
 Koert Hendrik Stefanus Pretorius      PDMR                    10 760                  £49 561
 Dr René Toua                          PDMR                     7 739                  £35 646
 Greg van Wyk                          PDMR                     6 241                  £28 746

The LTI Plan Awards granted to Dr Ronnie van der Merwe and Jurgens Myburgh on the same date will
also vest at 12.1% of maximum based on the achievement against performance targets, equating to
45 185 and 24 981 shares, respectively. These awards will also be cash settled (as permitted under the
remuneration policy in place at the time and indicated in the Company’s annual report for the financial
year ended on 31 March 2019), as soon as practicable after vesting on 18 June 2024.

For further information, please refer to page 160 of the Company’s annual report for the financial year
ended 31 March 2022.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.


1.   Details of PDMR / person closely associated with them (‘PCA’)

a)   Name                    David John Hadley

2.   Reason for the notification

a)   Position / status       Chief Executive Officer – Mediclinic Middle East

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                        Volume(s)
                             £nil                            16 621

d)   Aggregated
     information

     Aggregated volume       16 621

     Price                   £nil

e)   Date of the             20 June 2022
     transaction

f)   Place of the            London Stock Exchange
     transaction

1.   Details of PDMR / PCA

a)   Name                    Gert Cornelis Hattingh

2.   Reason for the notification

a)   Position / status       Group Chief Governance Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                        Volume(s)
                             £nil                            9 857

d)   Aggregated
     information

     Aggregated volume       9 857

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction
1.   Details of PDMR / PCA

a)   Name                    Dr Dirk Cornelius le Roux

2.   Reason for the notification

a)   Position / status       Group Chief Information Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                        Volume(s)
                             £nil                            7 739

d)   Aggregated
     information

     Aggregated volume       7 739

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction
1.   Details of PDMR / PCA

a)   Name                    Dr Daniel Liedtke

2.   Reason for the notification

a)   Position / status       Chief Executive Officer – Hirslanden


b)   Initial notification / Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature      of         the Award over ordinary shares in Mediclinic International plc granted at
     transaction            nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s)            and
     volume(s)              Price(s)                         Volume(s)
                            £nil                             15 610

d)   Aggregated
     information

     Aggregated volume      15 610

     Price                  £nil

e)   Date       of          the 20 June 2022
     transaction
f)   Place       of         the London Stock Exchange
     transaction
1.   Details of PDMR / PCA

a)   Name                    Magnus Oetiker

2.   Reason for the notification

a)   Position / status       Group Chief Strategy Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the          Award over ordinary shares in Mediclinic International plc granted at
     transaction            nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                        Volume(s)
                             £nil                            13 157

d)   Aggregated
     information

     Aggregated volume       13 157

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction

1.   Details of PDMR / PCA

a)   Name                    Koert Hendrik Stefanus Pretorius

2.   Reason for the notification

a)   Position / status       Group Chief Operating Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                        Volume(s)
                             £nil                            10 760

d)   Aggregated
     information

     Aggregated volume       10 760

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction

1.   Details of PDMR / PCA

a)   Name                    Dr René Toua

2.   Reason for the notification

a)   Position / status       Group Chief Clinical Officer – Mediclinic International plc

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted
a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                         Volume(s)
                             £nil                             7 739

d)   Aggregated
     information

     Aggregated volume       7 739

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction

1.   Details of PDMR / PCA

a)   Name                    Greg van Wyk

2.   Reason for the notification

a)   Position / status       Chief Executive Officer – Mediclinic Southern Africa

b)   Initial notification /  Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform,
     auctioneer or auction monitor
a)   Name                    Mediclinic International plc

b)   LEI                     2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
     each type of transaction; (iii) each date; and (iv) each place where transactions have
     been conducted

a)   Description of the      Ordinary Shares
     financial instrument

     Identification Code     GB00B8HX8Z88

b)   Nature of the           Award over ordinary shares in Mediclinic International plc granted at
     transaction             nil cost under the Company’s Long-Term Incentive Plan

c)   Price(s) and
     volume(s)               Price(s)                           Volume(s)
                             £nil                               6 241
d)   Aggregated
     information

     Aggregated volume       6 241

     Price                   £nil

e)   Date of the             20 June 2022
     transaction
f)   Place of the            London Stock Exchange
     transaction


About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and
four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals
(three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics
(four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the
Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1 000
inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom (‘UK’),
with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the UK and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 21-06-2022 05:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story